We are live on !
Find out more
Bartlett & Co Portfolio holdings
AUM
$6.16B
Turnover
12.86%
1-Year Est. Return
20.29%
This Fund
S&P 500
This Quarter Est. Return
+6.08%
1 Year Est. Return
+20.29%
3 Year Est. Return
+30.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.78B
AUM Growth
+$604M
(+12%)
Cap. Flow
+$315M
Cap. Flow % of AUM
Cap. Flow %
5.44%
Top 10 Holdings %
Top 10 Hldgs %
30.92%
Holding
1,221
New
145
Increased
296
Reduced
158
Closed
47
Avg Time Held
3.1
years
Top 10 Avg Time Held
3.9
years
Top 20 Avg Time Held
5.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chevron
CVX
|
+$21.8M |
| 2 |
Apple
AAPL
|
+$17.5M |
| 3 |
UnitedHealth
UNH
|
+$13.1M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$12.6M |
| 5 |
Cullen/Frost Bankers
CFR
|
+$12.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$18.1M |
| 2 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$4.79M |
| 3 |
US Bancorp
USB
|
+$4.28M |
| 4 |
Comcast
CMCSA
|
+$4.22M |
| 5 |
T. Rowe Price
TROW
|
+$4.17M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.66% |
| 2 | Miscellaneous | 17.21% |
| 3 | Healthcare | 12.66% |
| 4 | Financials | 11.11% |
| 5 | Industrials | 9.32% |
Similar funds
Bartlett & Co's Q2 2023 Portfolio in Review
As of Q2 2023, Bartlett & Co held 1,221 positions worth $5.78B, up 12% from $5.18B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Bartlett & Co deployed $315M of net new capital in Q2 2023, opening 145 new positions and adding to 296 existing holdings. Its largest new stake was Toro Company: 25,480 shares worth $2.6M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Miscellaneous and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $18.1M trimmed.
- Bartlett & Co's largest Q2 2023 buy was Toro Company: 25,480 shares worth $2.6M.
- Bartlett & Co added most to Chevron in Q2 2023, an estimated $21.8M increase.
- Bartlett & Co's biggest Q2 2023 reduction was Bristol-Myers Squibb, cutting an estimated $18.1M.
- Bartlett & Co fully exited iPath Pure Beta Broad Commodity ETN in Q2 2023, selling an estimated $684K.
- Bartlett & Co's ten largest holdings make up 31% of its $5.78B portfolio in Q2 2023.
- Bartlett & Co opened 145 new positions and closed 47 in Q2 2023.
- Bartlett & Co's portfolio value rose 12% quarter-over-quarter to $5.78B.
Based on Bartlett & Co's 13F filing for Q2 2023, filed 14 Jul 2023.